Načítá se...
U.S. prevalence of endocrine therapy–naïve locally advanced or metastatic breast cancer
BACKGROUND: Variations in treatment choice, or late stage at first diagnosis, mean that, despite guideline recommendations, not all patients with hormone receptor (hr)–positive locally advanced or metastatic breast cancer (la/mbca) will have received endocrine therapy before disease progression. In...
Uloženo v:
| Vydáno v: | Curr Oncol |
|---|---|
| Hlavní autoři: | , , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Multimed Inc.
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6476436/ https://ncbi.nlm.nih.gov/pubmed/31043825 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3747/co.26.4163 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|